Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine therapy improve the outcomes of patients with hormone-receptor (HR)-positive, HER2-negative advanced breast cancer and can be used early as first-line treatment or deferre...
[3]Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis.2022 ESMO abstract 169P. [4]Dukelow T, Kishan D, Khasraw M, et al. CDK4/6 inhibitors in breast cancer[J]. Anti-cancer drugs. 2015;...
[3]Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis.2022 ESMO abstract 169P. [4]Dukelow T, Kishan D, Khasraw M, et al. CDK4/6 inhibitors in breast cancer[J]. Anti-cancer drugs. 2015;...
Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are indicated with endocrinetherapyas first-line or second-line treatment for hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer. We aimed to investigate the benefit of adding CDKIs to endocrine therapy in patients whose tumo...
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine therapy improve the outcomes of patients with hormone-receptor (HR)-positive, HER2-negative advanced breast cancer and can be used early as first-line treatment or deferred to second-line treatment. Randomized data...
[3]Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis.2022 ESMO abstract 169P. [4]Dukelow T, Kishan D, Khasraw M, et al. CDK4/6 inhibitors in breast cancer[J]. Anti-cancer drugs. 2015...
Spring LM,Zangardi ML,Moy B.Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations[J].The oncologist,2017. do...
The SONIA study shows that early use of inhibitors that target both CDK4 and CDK6 (hereafter, CDK4/6) in metastatic breast cancer prolongs time on treatment but does not improve patient outcomes. Postponing innovative treatments to a later stage of the disease could thus safely reduce the time...
In this review we provide an up to date overview of the development of anti-cancer agents, particularly the newly developed CDK4/6 inhibitors. Material and methods: A search of PubMed was conducted to identify preclinical data surrounding the development of endocrine therapy and CDK4/6 ...
化疗改变Rb1突变后克服转移性乳腺癌患者对于CDK4/6抑制剂的耐药:病例报告及文献综述(Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review) 亮点 问:本病例报告在什么背景下进行的?